Design and validation of HIV peptide pools for detection of HIV-specific CD4⁺

and CD8⁺ T cells

Rita Alkolla¹, Alba Grifoni¹, Shane Crotty^{1,2,3}, Alessandro Sette^{1,2}, Sara Gianella², Jennifer Dan^{1,2,*}

¹Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA

² Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA

³Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA

*Corresponding author

E-mail: jdan@health.ucsd.edu

Abstract

Reagents to monitor T cell responses to the entire HIV genome, based on well characterized epitopes, are missing. Evaluation of HIV-specific T cell responses is of importance to study natural infection, and therapeutic and vaccine interventions. Experimentally derived CD4⁺ and CD8⁺ HIV epitopes from the HIV molecular immunology database were developed into Class I and Class II HIV megapools (MPs). We assessed HIV responses in persons with HIV pre combined antiretroviral therapy (cART) (n=17) and post-cART (n=18) and compared these responses to 15 controls without HIV (matched by sex, age, and ethnicity). Using the Activation Induced Marker (AIM) assay, we quantified HIV-specific total CD4⁺, memory CD4⁺, circulating T follicular helper, total CD8⁺ and memory CD8⁺ T cells. We also compared the Class I and Class II HIV MPs to commercially available HIV gag peptide pools. Overall, HIV Class II MP detected HIV-specific CD4⁺ T cells in 21/35 (60%) HIV positive samples and 0/15 HIV negative samples. HIV Class I MP detected an HIV-specific CD8⁺ T cells in 17/35 (48.6%) HIV positive samples and 0/15 HIV negative samples. Our innovative HIV MPs are reflective of the entire HIV genome, and its performance is comparable to other commercially available peptide pools. Here, we detected HIVspecific $CD4^+$ and $CD8^+$ T cell responses in people on and off cART, but not in people without HIV.

Introduction

The Human Immunodeficiency Virus (HIV) infects CD4⁺ T cells and, if unchecked, slowly obliterates the host immune response over time [1]. During initial infection, the host mounts an HIV-specific immune response with the development of HIV-specific CD4⁺ and CD8⁺ T cells [2– 4]. With combined antiretroviral treatment (cART), HIV RNA levels in blood fall below the limit of detection, and the host immune system is "restored" with a rebound in CD4⁺ T cell count [5,6]. The quality of HIV-specific CD4⁺ and CD8⁺ T cells depends on if these individuals are elite controllers or chronic progressors.

To understand the HIV host immune response, it is necessary to precisely identify and quantify HIV-specific T cells. Classic methodologies to detect HIV-specific CD4⁺ and CD8⁺ T cell responses have relied on intracellular cytokine staining. Major Histocompatibility Complex (MHC) tetramer binding assays, lymphoproliferative assays, and ELISpots [7]. Intracellular cytokine staining requires fixation of cells which cannot be used in subsequent functional assays or most gene expression analyses. MHC tetramer binding assays require foreknowledge of an individual's Human Leukocyte Antigen (HLA). Both lymphoproliferative assays and ELISpots require long term cultures during which cell phenotypes might change [8]. We therefore developed the Activation Induced Marker (AIM) assay to directly detect antigen-specific CD4⁺ T cells after a 24 hour cell culture [8–11]. The AIM assay is cytokine-independent and detects antigen-specific cells utilizing surface co-expression of specific activation markers, e.g. OX40, PD-L1, CD25, CD69, CD40L, and 41BB (CD137). Advantages of the AIM assay include (1) the ability to sort live cells by flow cytometry for subsequent assays or sequencing, (2) a short assay duration which limits detection of bystander activated cells, and (3) the ability to further classify antigen-specific T cells into different T cell memory subsets and T helper cell functions. For human lymphocytes,

marker combinations of CD25/OX40, OX40/PD-L1, OX40/41BB, OX40/CD40L, CD69/CD40L, and CD69/41BB have been used to detect antigen-specific CD4⁺ and CD8⁺ T cells [8,10,12–14].

The HIV proteins gag and env are major targets of HIV-specific CD4⁺ and CD8⁺ T cell responses [2,16–18]. Prior studies have demonstrated a correlation of gag-specific CD4⁺ T cells and viremic control, whereas the reverse have been observed with env-specific CD4⁺ T cells [16]. However, gag and env do not reflect the entirety of the host immune response to HIV viral proteins. Herein, we generated a Class I HIV-specific megapool (MP) and Class II HIV MP, reflective of the entire HIV proteome. Using the HIV molecular immunology database to extract experimentally derived HIV epitopes and Immune Epitope Database (IEDB) cluster tool [19], we designed a Class I HIV MP consisting of immunodominant peptides from env (envelope), gag, gp160 (polyprotein of env), nef, pol, rev, tat, vif, vpr, and vpu. We show that the Class I and Class II HIV MP are able to detect HIV-specific CD8⁺ and CD4⁺ T cells, respectively.

Materials and Methods

Study subjects

Peripheral blood mononuclear cells (PBMCs) were collected from people with HIV (PWH) precART and post-cART (Table 1) between 2001 and 2018. These 21 study participants were enrolled under the San Diego Primary Infection Research Consortium (PIRC) (<u>https://www.pirc.ucsd.edu</u>) [20]. These individuals were diagnosed early in their HIV infection and were followed longitudinally before and after cART initiation. Participants were recruited under a protocol approved by the Institutional Review Board (IRB) at the University of California, San Diego (UCSD). Blood specimens were taken from 11 individuals at an early time point post infection (21-138 days post the estimated date of infection). Nine of the 11 individuals had paired pre- and postcART specimens. One individual had only a pre-cART specimen and one individual had only a post-cART specimen.

Blood specimens were taken from 10 individuals who were chronically infected (441-3598 days post the estimated date of infection). Five of the 10 individuals had paired pre- and post-cART specimens. Two individuals had only a pre-cART specimen and three individuals had only a post-cART specimen.

As a control group, we used PBMCs from 15 HIV seronegative donors matched by sex, age, and ethnicity. Participants for the control group were recruited under a protocol approved by IRB at La Jolla Institute for Immunology (LJI).

HIV Megapools (MP)

HLA Class I and II restricted epitopes have been extracted from HIV molecular immunology database (https://www.hiv.lanl.gov/content/immunology/) using the T Helper/CD4⁺ Search and the CTL/CD8⁺ search [21]. The list of epitopes spanning all the HIV proteins (env, gag, gp160, nef, pol, rev, tat, vif, vpr, vpu) have been then clustered using the Epitope Cluster Analysis Tool 2.0 (http://tools.iedb.org/main/analysis-tools/) via the cluster-break method with a 70% homology cutoff, as previously described for other megapool generation [19,22]. The corresponding list of HIV peptides were synthesized by TC Peptide Lab (San Diego) as crude material on 1-2 mg scale. Individual peptides were resuspended in dimethyl sulfoxide (DMSO), pooled, and sequentially lyophilized, as previously reported. The resulting lyocake was resuspended in DMSO at a stock concentration of 1mg/mL. The Class I MP consists of 187 peptides (46 gag peptides, 34 gp160

peptides, 25 nef peptides, 59 pol peptides, 4 rev peptides, 2 tat peptides, 9 vif peptides, 6 vpr peptides, and 2 vpu peptides). The Class II MP consists of 164 peptides (7 env peptides, 5 gag peptides, 61 gp160 peptides, 15 nef peptides, 61 pol peptides, 2 rev peptides, 4 tat peptides, 1 vif peptides, 7 vpr peptides, and 1 vpu peptide). Peptides are listed in Supplemental Tables 1 and 2.

Other Antigens

CMV Class I and II peptide MPs were synthesized by TC Peptide Lab (San Diego) as crude material on 1-2 mg scale. Individual peptides were resuspended in DMSO and pooled into two different MPs for this study. The peptide pools were sequentially lyophilized and each pool resuspended at a stock concentration of 1mg/mL [8,23]. JPT HIV-1 gag peptide pool (JPT PepMix HIV (GAG) Ultra), consisting of 150 overlapping peptides of 15-mers with 11 amino acid overlap, was purchased from JPT Peptide Technologies. National Institutes of Health (NIH) HIV-1 Clade B gag peptide pool (NIH AIDS Reagent Program #12425), consisting of 123 overlapping peptides of 15-mers with 11 amino acid overlap, was provided by the AIDS Reagent Program. Each peptide pool (JPT and NIH) was suspended in DMSO at a final concentration of 1mg/mL.

PBMC Isolation

PBMCs were isolated from whole blood by density gradient centrifugation using Histopaque 1077 (Sigma) and cryopreserved in liquid nitrogen in fetal bovine serum containing 10% DMSO.

AIM Assays

Cells were cultured in RPMI supplemented with 5% human AB serum (Gemini Bioscience), Glutamax (Gibco), and Penicillin/Streptomycin (Gibco). Cryopreserved PBMCs were thawed and cultured at ~ $1x10^6$ cells per well in a 96 well round bottom plate. Cells were stimulated with peptides: HIV Class 1 MP (1µg/mL), HIV Class II MP (2µg/mL), HIV JPT gag peptide pool (2µg/mL), HIV NIH gag peptide pool (2µg/mL), CMV Class 1 MP (1µg/mL), and CMV Class II MP (2µg/mL). As a positive control, cells were stimulated with SEB (100ng/mL, Toxin Technology). As a negative control, cells were stimulated with media containing an equivalent volume of DMSO to the one used for the peptide stimulation. When cells were limiting, priority stimulations were HIV Class II MP > HIV Class I MP and CMV Class II MP > CMV Class I MP. Cells were cultured for 24 hours and stained by flow cytometry (FACS). FACS staining buffer consisted of 0.5% Bovine serum albumin (BSA) in phosphate buffered saline (PBS).

Cells were labeled with fixable viability dye eFluor 780 (Thermo Fisher Scientific). Antibodies from Thermo Fisher Scientific included CD19 e780 (clone HIB19), CD14 e780 (clone 61D3), CD16 e780 (clone eBioCB16), OX40 FITC (clone Ber-ACT35), CD69 PeCy7 (clone FN50). Antibodies from Biolegend included: CD45RA BV570 (clone HI100), CXCR5 BV421 (clone J252D4), PD-L1 PE (clone 29E.2A3), CCR7 APC (clone G043H7), CD8a BV650 (clone RPA-T8), CD4 PerCpCy5.5 (clone OKT4). Cells were acquired on a BD Celesta and analyzed using FlowJo Software, version 9.9.6. The frequency of antigen-specific cells was reported by background subtracting the frequency of antigen-specific responses from those of unstimulated cells per donor. Of note, one post-cART specimen did not have sufficient CD4 cells to assess HIVspecific CD4⁺ T cell responses.

Statistical Analyses

Statistical analyses were performed using GraphPad Prism 9. Non-parametric tests were used in all cases. Wilcoxon and Mann-Whitney U tests were used to compare the magnitude of responses. Fisher exact tests were used to compare the frequency of responders.

Results

Study Population

Men who have sex with men (MSM) with HIV were enrolled, from whom blood was taken pre-cART (n=17) and post-cART (n=18) (Table 1). The pre-cART median CD4⁺ T cell count was 606 cells/ul [interquartile range (IQR), 415-718]. The HIV RNA load was 120,000 copies/ml [IQR, 55,087 – 244,480] with a median estimated date of infection of 98 days [IQR, 74-2004] at the time of sample collection. The post-cART median CD4⁺ T cell count was 825 cells/ul [IQR, 563-1025]. The HIV RNA load was below the limit of detection with a median of 667 days [IQR, 495-1388] from beginning cART and a median of 236 days [162-644] from starting cART till an undetectable HIV viral load.

Pre-cART (n=17)	[Median, IQR]
Age (Years)	39 [29 - 43]
Time from ^a EDI (days)	98 [74 - 2004]
CD4 (cells/mm ³)	606 [415 - 718]
HIV viral load (copies/mL)	120,000 [55,087 – 244,480]
Gender	

Table 1. Clinical Characteristics of HIV positive patients.

Male (%)	100%
Ethnicity	
Hispanic (%)	11.8%
Non-Hispanic (%)	88.2%
Race	
White (%)	82.3%
Black (%)	5.9%
Other (%)	11.8%
Sexual Orientation	
MSM (%)	100%

Post-cART (n=18)	[Median, IQR]
Age (Years)	40 [33 - 46]
Time from EDI (days)	983 [672 – 2838]
Time from cART (days)	667 [495 – 1388]
Time from cART to undetectable HIV viral	236 [162 - 644]
load (days)	
CD4 (cells/mm ³)	825 [563 - 1025]
HIV viral load (copies/mL)	50 [45 - 50]
Gender	
Male (%)	100%
Ethnicity	
Hispanic (%)	22.2%

Non-Hispanic (%)	77.8%
Race	
White (%)	77.7%
Black (%)	5.6%
Other (%)	16.7%
Sexual Orientation	
MSM	100%

^aEDI: estimated date of infection

Detection of HIV-specific CD4⁺ T cells

Using a Class II HIV MP consisting of immunodominant epitopes from the entire HIV proteome, we first tested its ability to detect HIV-specific CD4⁺ T cells in HIV positive and HIV negative samples. In HIV-specific CD4⁺ T cells, there is lower 41BB expression, attributed to T-cell exhaustion from chronic infection which precludes use of 41BB by AIM assay [15]. Additionally, a combination of CD25/OX40 on PBMCs captures more T regulatory cells which may be elevated in chronic infections [10]. We thus identified HIV-specific CD4⁺ T cells by a combination of OX40 and PD-L1 by AIM assay (Fig 1A) [10]. Higher magnitudes of HIV-specific CD4⁺ T cells responses were detected for pre-cART (p=0.00073) and post-cART samples (p=0.0061) compared to HIV negative samples, with a limit of sensitivity of 0.05% (Fig 1B). There was no difference in the proportion of responders detected pre-cART (11/17) and post-cART (10/18) by the Fisher Exact test with a sensitivity of 62.85% and a specificity of 100%, inclusive of paired pre- and post-cART specimens.

Fig 1. Detection of HIV-specific CD4⁺ T cells. (A) Sample flow cytometry plot showing gating strategy for HIV-specific CD4⁺ T cells based on co-expression of OX40 and PD-L1 on total CD4, memory CD4, and cTfh cells. Specimens from HIV infected donors have a higher frequency of (B) HIV-specific total CD4⁺ T cells, (C) HIV-specific memory CD4⁺ T cells, and (D) HIV-specific cTfh cells compared to HIV uninfected specimens. There was no statistical difference between pre- and post-cART specimens. Data was background subtracted. Statistics by Mann-U Whitney test.

As the memory T cell compartment is important in chronic infection, we quantified memory CD4⁺ T cells. We identified HIV-specific total memory CD4⁺ T cells and circulating T follicular helper (Tfh) cells. We defined total memory CD4⁺ T cells as a combination of central memory + effector memory + T_{EMRA} (Fig 1A). Higher magnitudes of HIV-specific memory CD4⁺ T cell responses were detected in both pre- (p=0.0019) and post-cART HIV-infected individuals (p=0.011, Mann-Whitney) compared to HIV negative individuals (Fig 1C). There was no difference in the proportion of responders pre- (12/17) and post-cART (12/18) by Fisher Exact. Circulating Tfh (cTfh) cells are CD4⁺ T cells which provide help to B cells to promote the development high affinity antibodies [24]. We defined cTfh cells by CCR5⁺CD45RA⁻ CD4⁺ T cells (Fig 1A). Similarly, higher magnitudes of HIV-specific cTfh tells were detected in pre- (p=0.0024) and post-cART HIV-infected individuals (p=0.00028) compared to HIV negative individuals (Fig 1D). There was no difference in the proportion of responders pre- (12/17) and post-cART (13/18) by the Fisher Exact test.

Detection of HIV-specific CD8⁺ T cells

Using a Class I HIV MP consisting of immunodominant epitopes from the entire HIV proteome, we tested its ability to detect HIV-specific CD8⁺ T cells in HIV positive and HIV negative samples. By co-expression of CD69 and PD-L1 by AIM assay (Fig 2A), we detected HIV-specific CD8⁺ T cells. The Class I HIV MP detected total CD8⁺ T cells in 11/17 pre-(p=0.0087) and 6/18 post-ART (p=NS) compared to 0/15 HIV negative individuals, with a limit of sensitivity of 0.05% (Fig 2B). For memory CD8⁺ T cells, HIV Class I MP detected 10/17 pre-ART specimens (p=0.021) and 5/18 post-cART specimens (p=NS) compared to 0/15 HIV negative individuals (Fig 2C). There was no difference in the magnitude of CD8⁺ T cell or memory CD8⁺ T cell responses between pre- and post-cART timepoints. The Class I HIV MP had a 48.6% sensitivity and 100% specificity.

Fig 2. Detection of HIV-specific CD8⁺ T cells. (A) Sample flow cytometry plot showing gating strategy for HIV-specific CD8⁺ T cells based on co-expression of CD69 and PD-L1 on total CD8 and memory CD8 T cells. Specimens from HIV infected donors have a higher frequency of (B) HIV-specific total CD8⁺ T cells and (C) HIV-specific memory CD8⁺ T cells compared to HIV negative specimens. There was no statistical difference between pre- and post-cART specimens. Data was background subtracted. Statistics by Mann-U Whitney test.

Comparison of HIV MP to commercially available gag peptide pools

The detection of gag-specific T cells is the most common way to quantify HIV-specific T cells. We therefore compared the Class I and II HIV MP to 2 commercially available gag peptide pools from JPT and NIH. The frequencies of HIV-specific CD4⁺ T cells, memory CD4⁺ T cells,

and cTfh were comparable when using the Class II MP, JPT gag, or NIH gag peptide pools (S1A-S1F Figs). The frequencies of HIV-specific total CD8⁺ T cells and memory CD8⁺ T cells were also comparable (S2A-S2D Figs).

Supplemental Fig 1. Comparison of HIV-specific CD4⁺ T-cell responses. Comparison of responses between HIV Class II MP, JPT gag, and NIH gag for HIV-specific total CD4⁺ T cells in pre-cART (A) and post-AcRT (B) specimens, HIV-specific memory CD4⁺ T cells in pre-cART (C) and post-cART (D) specimens, and HIV-specific cTfh cells in pre-cART (E) and post-cART (F) specimens. Data was background subtracted. Statistics by Wilcoxon test.

Supplemental Fig 2. Comparison of HIV-specific CD8⁺ T-cell responses. Comparison of responses between HIV Class I MP, JPT gag, and NIH gag for HIV-specific total CD8⁺ T cells in pre-cART (A) and post-cART (B) specimens and HIV-specific memory CD8⁺ T cells in pre-cART (C) and post-cART (D) specimens. Data was background subtracted. Statistics by Wilcoxon test.

Detection of CMV-specific CD4⁺ and CD8⁺ T cells

To demonstrate our ability to detect antigen-specific T cells, as a control, we tested for CMV-specific T cells in these same specimens [25,26]. Using our Class II MP, we were able to detect CMV-specific CD4⁺ T-cells. The magnitudes of CMV-specific CD4⁺ T cells were comparable pre- and post-cART for total CD4⁺ T cells, memory CD4⁺ T cells, and cTfh (S3A-S3C Figs). Using the Class I CMV MP, we additionally tested the magnitudes of CMV-specific CD8⁺ T cells pre- and post-cART. There was no difference between the magnitudes of total and memory CMV-specific CD8⁺ T cell among pre- and post-cART specimens and HIV negative

individuals (S3D-S3E Figs).

Supplemental Fig 3. Comparison of CMV-specific responses. Class II MP detects CMV-specific (A) total CD4⁺ T cells, (B) memory CD4⁺ T cells, and (C) cTfh cells. CMV Class I MP detects CMV-specific (D) total CD8⁺ T cells and (E) memory CD8⁺ T cells. Data was background subtracted. Statistics by Mann-U Whitney test.

Discussion

The HIV MP was designed to encompass all HIV proteins instead of only gag, as other HIV proteins such as nef [17,27,28], pol [29], and tat [30] can elicit HIV-specific T cell responses. Using the Class I and Class II MP reflective of the immunodominant epitopes from the entire HIV proteome, we were able to detect at least either HIV-specific CD4⁺, memory CD4⁺ T, cTfh, CD8⁺ T, or memory CD8⁺ cells in 20/21 (95%) of PWH. Prior studies have demonstrated that 81% of individuals with acute HIV infection had detectable gag-specific CD4⁺ T cells [17] whereas up to 83% had detectable gag-specific CD8⁺ T cells [28]. The one participant in whom we could not detect HIV-specific T-cells had detectable CMV-specific CD8⁺ T cells. For the JPT and NIH gag peptide pools, 19/21 (90%) PWH had either a detectable HIV-specific CD4⁺, memory CD4⁺ T, cTfh, CD8⁺ T, or memory CD8⁺ cells. With regards to detection of HIV-specific T cells in precART (n=17) and post-cART (n=18) specimens, using the HIV MPs, we were unable to detect HIV-specific T cells or their subsets in 1 pre-cART specimen and 4 post-cART specimens. This is consistent with prior studies, in which cART treated individuals have lower frequencies of HIVspecific CD4⁺ and CD8⁺ T cells [4,16,31]. Overall, our HIV Class I and Class II MP were comparable in their ability to detect HIV-specific responses to the gag peptide pools alone,

regardless of acute or chronic infection.

PWH are almost universally co-infected with CMV [32]. Our HIV cohort were all CMV IgG seropositive. We were able to detect CMV-specific CD4⁺, memory CD4⁺ T, cTfh, CD8⁺ T, or memory CD8⁺ cells in 21/21 (100%) of PWH.

Limitations of this study include a small sample size comprising entirely of MSM. These individuals comprised both acute infections which were treated early and chronic infections. The frequency of HIV-specific CD4⁺ T cells vary with duration of viremia and therefore antigen exposure, particularly if the patient is suppressed on cART which removes detectable antigen from the bloodstream versus an elite controller [16]. Our cohort consisted of patients with an estimated date of infection ranging from 21 to 3598 days in our pre-cART specimens and time to undetectable viral load ranging from 81 to 1620 days in our post-cART specimens. Moreover, as these participants were enrolled over 2 decades, there were varying cART regimens which differ from today's first line treatment options. However, we did not observe a clear correlation with T cell responses and cART used.

In summary, we describe an innovative Class I and Class II HIV MP, reflective of the entire HIV proteome, which can be used in future studies to better understand the full repertoire of HIVspecific CD4⁺ and CD8⁺ T cell dynamics. The AIM assay allows for easy quantification of antigenspecific T cells. This methodology permits sorting of live antigen-specific T cells for further functional analyses, allowing for sequencing of CD4⁺ and CD8⁺ subsets, including Tfh cells [8]. These HIV-specific CD4⁺ and CD8⁺ T cells could be sorted and sequenced in hyperacute infections [3] and/or HIV exposed but seronegative individuals [33] and compared to cART treated individuals or elite controllers to assess transcriptomic differences [2].

REFERENCES

1. Okoye AA, Picker LJ. CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254: 54–64. doi:10.1111/imr.12066

2. Morou A, Brunet-Ratnasingham E, Dubé M, Charlebois R, Mercier E, Darko S, et al. Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease. Nat Immunol. 2019;20: 1059–1070. doi:10.1038/s41590-019-0418-x

3. Ndhlovu ZM, Kazer SW, Nkosi T, Ogunshola F, Muema DM, Anmole G, et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Sci Transl Med. 2019;11: eaau0528. doi:10.1126/scitranslmed.aau0528

4. Behrens NE, Wertheimer A, Love MB, Klotz SA, Ahmad N. Evaluation of HIV-specific Tcell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy. Plos One. 2020;15: e0236320. doi:10.1371/journal.pone.0236320

5. Ford N, Meintjes G, Vitoria M, Greene G, Chiller T. The evolving role of CD4 cell counts in HIV care. Curr Opin Hiv Aids. 2017;12: 123–128. doi:10.1097/coh.00000000000348

 Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, et al. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy. New Engl J Medicine. 2013;368: 218–230. doi:10.1056/nejmoa1110187 7. Maecker H, Maino V. T Cell Immunity to HIV: Defining Parameters of Protection. Curr Hiv Res. 2003;1: 249–259. doi:10.2174/1570162033485294

 8. Dan JM, Arlehamn CSL, Weiskopf D, Antunes R da S, Havenar-Daughton C, Reiss SM, et al. A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood. J Immunol Baltim Md 1950. 2016;197: 983–93. doi:10.4049/jimmunol.1600318

9. Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Peña AT de la, et al. Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. J Immunol Baltim Md 1950. 2016;197: 994–1002. doi:10.4049/jimmunol.1600320

10. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. Plos One. 2017;12: e0186998. doi:10.1371/journal.pone.0186998

11. Antunes R da S, Paul S, Sidney J, Weiskopf D, Dan JM, Phillips E, et al. Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. Plos One. 2017;12: e0169086.
doi:10.1371/journal.pone.0169086

12. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181: 1489-1501.e15. doi:10.1016/j.cell.2020.05.015 13. Moderbacher CR, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183: 996-1012.e19. doi:10.1016/j.cell.2020.09.038

14. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; eabf4063. doi:10.1126/science.abf4063

15. Kassu A, D'Souza M, O'Connor BP, Kelly-McKnight E, Akkina R, Fontenot AP, et al. Decreased 4-1BB expression on HIV-specific CD4+ T cells is associated with sustained viral replication and reduced IL-2 production. Clin Immunol. 2009;132: 234–245. doi:10.1016/j.clim.2009.03.531

16. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, et al. HIVspecific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2011;86: 277–83. doi:10.1128/jvi.05577-11

17. Schieffer M, Jessen HK, Oster AF, Pissani F, Soghoian DZ, Lu R, et al. Induction of Gagspecific CD4 T cell responses during acute HIV infection is associated with improved viral control. J Virol. 2014;88: 7357–66. doi:10.1128/jvi.00728-14

18. Wendel BS, Alcazar DD, He C, Río-Estrada PMD, Aiamkitsumrit B, Ablanedo-Terrazas Y, et al. The receptor repertoire and functional profile of follicular T cells in HIV-infected lymph nodes. Sci Immunol. 2018;3: eaan8884. doi:10.1126/sciimmunol.aan8884

19. Dhanda SK, Vaughan K, Schulten V, Grifoni A, Weiskopf D, Sidney J, et al. Development of a novel clustering tool for linear peptide sequences. Immunology. 2018;155: 331–345.doi:10.1111/imm.12984

20. Morris SR, Zhao M, Smith DR, Vargas MV, Little SJ, Gianella S. Longitudinal Viral Dynamics in Semen During Early HIV Infection. Clin Infect Dis. 2016;64: ciw784. doi:10.1093/cid/ciw784

21. Yusim K, Korber BTM, Barouch D, Koup R, Boer R de, Moore JP, et al. HIV Molecular Immunology 2014. doi:10.2172/1169681

22. Grifoni A, Angelo MA, Lopez B, O'Rourke PH, Sidney J, Cerpas C, et al. Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. Front Immunol. 2017;8: 1309. doi:10.3389/fimmu.2017.01309

23. Pro SC, Sidney J, Paul S, Arlehamn CL, Weiskopf D, Peters B, et al. Automatic Generation of Validated Specific Epitope Sets. J Immunol Res. 2015;2015: 763461.doi:10.1155/2015/763461

24. Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity.2019;50: 1132–1148. doi:10.1016/j.immuni.2019.04.011

25. Gianella S, Massanella M, Richman DD, Little SJ, Spina CA, Vargas MV, et al. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014;88: 7818–27. doi:10.1128/jvi.00831-14 26. Dan JM, Massanella M, Smith DM, Spina CA, Schrier R, Daar ES, et al. Brief Report: Effect of CMV and HIV Transcription on CD57 and PD-1 T-Cell Expression During Suppressive ART.J Acquir Immune Defic Syndromes 1999. 2016;72: 133–7. doi:10.1097/qai.00000000000936

27. Pancré V, Delhem N, Yazdanpanah Y, Delanoye A, Delacre M, Depil S, et al. Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection. Vaccine. 2007;25: 5927–5937. doi:10.1016/j.vaccine.2007.05.038

28. Radebe M, Gounder K, Mokgoro M, Ndhlovu ZM, Mncube Z, Mkhize L, et al. Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. Aids. 2015;29: 23–33.

doi:10.1097/qad.000000000000508

29. Kallas EG, Grunenberg NA, Yu C, Manso B, Pantaleo G, Casapia M, et al. Antigenic competition in CD4 + T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. Sci Transl Med. 2019;11: eaaw1673. doi:10.1126/scitranslmed.aaw1673

30. Meddows-Taylor S, Shalekoff S, Kuhn L, Gray GE, Tiemessen CT. Development of a whole blood intracellular cytokine staining assay for mapping CD4+ and CD8+ T-cell responses across the HIV-1 genome. J Virol Methods. 2007;144: 115–121. doi:10.1016/j.jviromet.2007.04.004

31. Chevalier MF, Didier C, Girard P-M, Manea ME, Campa P, Barré-Sinoussi F, et al. CD4 T-Cell Responses in Primary HIV Infection: Interrelationship with Immune Activation and Virus Burden. Front Immunol. 2016;7: 395. doi:10.3389/fimmu.2016.00395

32. Christensen-Quick A, Massanella M, Frick A, Rawlings SA, Spina C, Vargas-Meneses M, et al. Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy. J Virol. 2019;93. doi:10.1128/jvi.00179-19

33. Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, et al. Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals †. J Virol. 2011;85: 3507–3516. doi:10.1128/jvi.02444-10

Supplemental Table 1. List of HIV class I peptides.

			Mapped Start	Mapped End
sequence	length	protein	Position	Position
GELDRWEKI	9	Gag	11	19
KIRLRPGGKK	10	Gag	18	27
IRLRPGGKKKY	11	Gag	19	29
RLRPGGKKKYKL	12	Gag	20	31
RPGGKKKYKLK	11	Gag	22	32
KYKLKHIVW	9	Gag	28	36
HLVWASRELERF	12	Gag	33	44
ELRSLYNTV	9	Gag	74	82
medRxiv preprint doi: https://doi.org/10.1101/2022.04-29.22 (which was not doctined by peer revery is the author/fu It is made available u	274468; this version nder, who has gran	n posted May 1, 2022 ted medRxiv a licens	2. The copyright holder for the to display the preprint i	
It is made available u	inder a CC-BY 4.0 I	nternational license . Gag	84	91
IEIKDTKEAL	10	Gag	92	101
NSSKVSQNY	9	Gag	124	132
VQNLQGQMV	9	Gag	135	143
HQAISPRTLNAW	12	Gag	144	155
VKVIEEKAF	9	Gag	156	164
EEKAFSPEVI	10	Gag	160	169
KAFSPEVIPMF	11	Gag	162	172
EVIPMFSAL	9	Gag	167	175
SEGATPQDL	9	Gag	176	184
TPQDLNMML	9	Gag	180	188
GHQAAMQML	9	Gag	193	201
KETINEEAAEW	11	Gag	202	212
AEWDRVHPV	9	Gag	210	218
HPVHAGPIA	9	Gag	216	224
GQMREPRGSDI	11	Gag	226	236
TSTLQEQIGW	10	Gag	240	249
NPPIPVGDIY	10	Gag	253	262
EIYKRWII	8	Gag	260	267
KRWIILGLNK	10	Gag	263	272
RRWIQLGLQK	10	Gag	263	272
GLNKIVRMY	9	Gag	269	277
VRMYSPVSI	9	Gag	274	282
YSPVSILDI	9	Gag	277	285
FRDYVDRFFKTL	12	Gag	293	304
DRFYKTLRA	9	Gag	298	306
AEQASQEVKNWM	12	Gag	306	317
VKNWMTETL	9	Gag	313	321
DCKTILKAL	9	Gag	329	337
ACQGVGGPGHK	11	Gag	349	359
GPGHKARVL	9	Gag	355	363
AEAMSQVTNS	10	Gag	364	373
CRAPRKKGC	9	Gag	405	413

TEDOANEI	0	Car	407	42.4	
TERQANFL	8	Gag	427	434	
RQANFLGKI	9	Gag	429	437	
FLGKIWPSYK	10	Gag	433	442	
KELYPLTSL	9	Gag	481	489	
RVKEKYQHL	9	gp160	2	10	
AENLWVTVYY	10	gp160	31	40	
TVYYGVPVWK	10	gp160	37	46	
VPVWKEATTTL	11	gp160	42	52	
LFCASDAKAY	10	gp160	52	61	
KAYETEVHNVW	11	gp160	59	69	
DPNPQEVVL	9	gp160	78	86	
MHEDIISLW	9	gp160	104	112	
SVITOACPK medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.2227 (which was not certified by peer (dview)) is the author/fund It is made available und	4468; this vers	ion posted May 1, 2022.	The copyright holder for	this preprint 217	
(which was not certified py peer review) is the author/fund It is made available und	er, whomas gra er a CC-BY 4.0	anteu neux iv a license : D International license .	o displaying preprint in	perpetuity. 217	
CAPAGFAIL	9	gp160	218	226	
RPNNNTRKSI	10	gp160	298	307	
HIGPGRAFY	9	gp160	310	318	
RGPGRAFVTI	10	gp160	311	320	
EIIGDIRQAY	10	gp160	321	330	
SFNCGGEFF	9	gp160	375	383	
LPCRIKQII	9	gp160	416	424	
RIKQIINMW	-	gp160	419	427	
RAIEAQQHM	9	gp160	557	565	
QTRVLAIERYL ERVLKDOOLL	11	gp160	577	587	
ERYLKDQQLL	10 9	gp160	584	593	
TAVPWNASW VEAVL SIVNB		gp160	606	614	
VFAVLSIVNR	10 9	gp160	698 704	707	
IVNRNRQGY RLRDLLLIVTR		gp160	704	712	
IVTRIVELL	11 9	gp160	770	780	
		gp160	777	785	
GRRGWEALKY KYCWNLLQY	10 9	gp160	786 794	795 802	
QELKNSAVSL		gp160	805	802	
SLLNATDIAV	10 10	gp160 gp160	803	814	
EVAQRAYR	8	•••	831	838	
IPRRIRQGL	9	gp160 gp160	843	851	
RIRQGLERA	9	gp160 gp160	845	854	
RQGLERALL	9	gp160 gp160	848	856	
WPTVRERM	8	Nef	13	20	
RMRRAEPAA	9	Nef	19	20	
LEKHGAITS	9	Nef	37	45	
FPVTPQVPLR	10	Nef	68	77	
RPOVPLRPMTY	11	Nef	71	81	
RPQVPLRPMTYK	12	Nef	71	82	
PLRPMTYKAA	10	Nef	75	84	
LRPMTYKAAL	10	Nef	76	85	
LINIMITIKAAL	10	INCI	10	05	

KAAVDLSHFL	10	Nef	82	91
KAAVDLSHFLK	11	Nef	82	92
GAFDLSFFL	9	Nef	83	91
FLKEKGGL	8	Nef	90	97
KEKGGLEGL	9	Nef	92	100
KRQDILDLWVY	11	Nef	104	115
RRQDILDLWVY	11	Nef	105	115
HTQGYFPDWQNY	12	Nef	116	127
TQGYFPDWQNYT	12	Nef	117	128
YFPDWQNYTP	10	Nef	120	129
YTPGPGIRY	9	Nef	127	135
TPGPGVRYPL	10	Nef	128	137
TRYPLTFGW	9	Nef	133 The convright holder for th	141
medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.222 (which was not certified by peer review) is the author/fur It is made available ur	nder, who has gran nder a CC-BY 4.0	International license	to display the preprint in pe	erpetuity. 143
YPLTFGWCYKL	11	Nef	135	145
VLEWRFDSRL	10	Nef	180	189
WRFDSRLAF	9	Nef	183	191
NSPTRREL	8	Pol	24	31
ITLWQRPLV	9	Pol	59	67
DTVLEEWNL	9	Pol	86	94
EEMNLPGRW	9	Pol	90	98
RQYDQILIEI	10	Pol	113	122
GKKAIGTVLV	10	Pol	124	133
LVGPTPVNI	9	Pol	132	140
TPVNIIGRNML	11	Pol	136	146
FPISPIETV	9	Pol	155	163
IETVPVKL	8	Pol	160	167
GPKVKQWPL	9	Pol	173	181
ALVEICTEMEK	11	Pol	188	198
KLVDFRELNK	10	Pol	228	237
GIPHPAGLK	9	Pol	248	256
TVLDVGDAY	9	Pol	262	270
VPLDEDFRKY	10	Pol	273	282
YTAFTIPSV	9	Pol	282	290
NETPGIRYQY	10	Pol	292	301
IRYQYNVL	8	Pol	297	304
LPQGWKGSPA	10	Pol	304	313
SPAIFQSSM	9	Pol	311	319
AIFQSSMTK	9	Pol	313	321
KQNPDIVIY	9	Pol	328	336
HPDIVIYQY	9	Pol	330	338
NPEIVIYQY	9	Pol	330	338
VIYQYMDDL	9	Pol	334	342
IEELRQHLL	9	Pol	357	365
IVLPEKDSW	9	Pol	399	407
LVGKLNWASQIY	12	Pol	415	426
				.20

OWDOWND	0	D-1 404	420	
QIYPGIKVR	9	Pol 424	432	
YPGIKVRQL IDL TEE A EL	9	Pol 426	434	
IPLTEEAEL	9	Pol 448	456	
ILKEPVHGVY	10	Pol 464	473	
GQGQWTYQI	9	Pol 488	496	
IYQEPFKNLK	10	Pol 496	505	
RMRGAHTNDVK	11	Pol 511	521	
IAMESIVIW	9	Pol 530	538	
PIQKETWETW	10	Pol 547	556	
GAETFYVDGAANR	13	Pol 591	603	
ETKLGKAGY	9	Pol 604	612	
IVTDSQYALGI	11	Pol 650	660	
OIIEOLIKK medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.222744 (which was not certified by ree (review)) is the author/funder It is made available under	168; this ve	ersion posted May 1, 2022. The copyright holder for this preprint	683	
It is made available under	a CC-BY	4.0 International license .	723	
LPPIVAKEI THLEGKIIL	9 9	101 745	151	
	9	Pol 781	789	
HVASGYIEA	10	Pol 793 Pol 799	801 808	
IEAEVIPAET HTDNGSNF	8		836	
STTVKAACWW	10	Pol 829 Pol 838	847	
IQQEFGIPY	9		858	
	8	Pol 850 Pol 880	887	
VRDQAEHL	9	Pol 880 Pol 888	896	
KTAVQMAVF AVFIHNFKRK	10	Pol 894	903	
FKRKGGIGGY	10		903	
GERIVDII	8	Pol 900 Pol 912	909 919	
IIATDIQTK	9	Pol 912 Pol 918	919 926	
KIQNFRVYY	9	Pol 934	942	
VPRRKAKII	9	Pol 975	983	
RKAKIIRDY	9	Pol 978	986	
KAVRLIKFLY	10	Rev 14	23	
QAVRIIKILY	10	Rev 14	23	
ERILSTYLGR	10	Rev 57	66	
RPAEPVPLQL	10	Rev 66	75	
CCFHCQVC	8	Tat 30	37	
FQTKGLGISYGR	12	Tat 38	49	
RIRTWKSLVK	10	Vif 17	26	
HMYISKKAK	9	Vif 28	36	
ISKKAKGWF	9	Vif 31	39	
HPRVSSEVHI	10	Vif 48	57	
IPLGDAKLII	10	Vif 57	66	
WHLGHGVSI	9	Vif 79	87	
LGHGVSIEW	9	Vif 81	89	
LADQLIHLHY	10	Vif 102	111	
KTKPPLPSVKK	11	Vif 158	168	
EAVRHFPRIW	10	Vpr 29	38	

AVRHFPRIWL	10	Vpr	30	39
FPRIWLHGL	9	Vpr	34	42
ETYGDTWTGV	10	Vpr	48	57
DTWAGVEAIIR	11	Vpr	52	62
AIIRILQQL	9	Vpr	59	67
YRLGVGALI	9	Vpu	5	13
EYRKILRQR	9	Vpu	29	37

Supplemental Table 2. List of HIV class II peptides.

			Mapped Start	Mapped End
sequence	length	protein	Position	Position
NCSFNATTVVRDRDQ	15	env	156	170
NATTVVRDRKQTVYA	15	env	160	174
VYALFYRLDIVPLTK	15	env	172	186
RIHIGPGRAFYTTKN	15	env	308	322
TGDIIGDIRQAHCNI	15	env	319	333
GIIGDIRQAHCHVSR	15	env	321	335
GAINTTNETFRPGGG	15	env	459	473
medRxiv preprint both tes://wiron//011012042.04.99.22124468; this v (which was not certified by peer review) is the author/funder, who has	version posted May 1	, 2022. The copyright ho	older for this preprint	443
GRPGNFLUSSRPEPIA	4.0 International lice	ense . gag	443	457
ESFRSGVETTTPPQK	15	gag	461	475
EPIDKELYPLASLRS	15	gag	477	491
DKELYPLASLRSLFG	15	gag	480	494
TEKLWVTVYYGVPVW	15	gp160	31	45
WVTVYYGVPVWKDAE	15	gp160	35	49
GATTTLFCASDAKAY	15	gp160	47	61
TTLFCASKAKAYDTE	15	gp160	50	64
THACVPADPNPQEMV	15	gp160	71	85
ENVTENFNMWKNEMV	15	gp160	87	101
ENFNMWKNEMVNQMQ	15	gp160	91	105
EMVNQMQEDVISLWD	15	gp160	99	113
SLKPCVKLTPLCVSL	15	gp160	115	129
CVKLTPLCVTLECRN	15	gp160	119	133
KNCSFNISTSIRGKV	15	gp160	155	169
DKMQKEYALLYKLDI	15	gp160	167	181
INCNTSAITQACPKV	15	gp160	194	208
VITQACPKVSFEPIP	15	gp160	200	214
PKVTFDPIPIHYCTP	15	gp160	206	220
FDPIPIHYCTPAGYA	15	gp160	210	224
PAGFAILKCNNKTFN	15	gp160	220	234
TNVSTVQCTHGRPIY	15	gp160	240	254
RPVVSTQLLLNGSLA	15	gp160	252	266
PVVSTQLLLNGSLAE	15	gp160	253	267
EVVIRSANFTDNAKT	15	gp160	269	283
IRSENITNNAKTIIV	15	gp160	272	286
SANFTDNAKTIIVQL	15	gp160	274	288
RIQRGPGRAFVTIGK	15	gp160	308	322
EQRGPGRAFVTIGKI	15	gp160	309	323
GRAFVTIGKIGNMRQ	15	gp160	314	328

CNISRAQWNNTLEQI	15	gp160	331	345
SSGGKPEIVTHSFNC	15	gp160	364	378
PEIVTHSFNCGGEFF	15	gp160	369	383
GEFFYCNSTQLFNST	15	gp160	380	394
EFFYCNTTQLFNNTW	15	gp160	381	395
TQLFNSTWFNSTWST	15	gp160	388	402
TWFNSTWSTKGSNNT	15	gp160	394	408
TWSTKGSNNTEGSDT	15	gp160	399	413
SSSIITIPCRIKQII	15	gp160	410	424
TIPCRIKQIINMWQE	15	gp160	415	429
IIKQIINMWQEVGRA	15	gp160	419	433
RIKQIINMWQKVGKA	15	gp160	419	433
RIKOIINMWOKVGKA medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.22274468; this ve (which was not certified by preprior event is the author/funder, who has it is made available under a CC-BY	granted medRxiv 4.0 International li	a license to display the prepr cense .	int in perpetoity.	435
INMWQEVGKAMYAPP	15	gp160	424	438
VGRAMYAPPIKGNIT	15	gp160	430	444
PIKGNITCKSNITGL	15	gp160	438	452
GNSNNESEIFRPGGG	15	gp160	459	473
ETFRPGGGDMRNNWR	15	gp160	466	480
DMRDNWRSELYKYKV	15	gp160	474	488
ELYKYKVVEIKPLGV	15	gp160	482	496
YKVVEIKPLGVAPTT	15	gp160	486	500
GIVQQQNNLLRAIEA	15	gp160	547	561
QQHLLQLTVWGIKQL	15	gp160	562	576
LTVWGIKQLQARVLA	15	gp160	568	582
GIKQLQARVLAVERY	15	gp160	572	586
EQIWNHTTWMEWDRE	15	gp160	620	634
EESQNQQEKNEQELL	15	gp160	647	661
ASLWNWFNITNWLWY	15	gp160	667	681
IKLFIMIVGGLVGLR	15	gp160	682	696
RTFIMIVGGLIGLRI	15	gp160	683	697
FVVLSIVNRVRQGYS	15	gp160	699	713
DRVIEVVGQAYRAIR	15	gp160	827	841
DRVIEVVQGAYRAIR	15	gp160	827	841
AIRHIPRRIRQGLER	15	gp160	839	853
HIPRRIRQGLERILL	15	gp160	842	856
GKWSKSSIVGWSAVR	15	nef	3	17
WSKSSIVGWPAVRER	15	nef	5	19
LEKHGAITSSNTAAT	15	nef	37	51
SSNTAATNAACAWLE	15	nef	45	59
EVGFPVIPQVPLRPM	15	nef	65	79
FPVRPQVPLRPMTYR	15	nef	68	82
QVPLRPMTYKGALDL	15	nef	73	87
AVDLSHFLKEKGGLM	15	nef	84	98

GWFLKEKGGLDGLIY	15	nef	88	102	
SWFLKEKGGLEGLIY	15	nef	88	102	
GWPFKLVPVDPREVQ	15	nef	140	154	
EVLMWKFDSRLAFHH	15	nef	179	193	
VLEWRFDSRLAFHHV	15	nef	180	194	
RWEFDSSLARRHLAR	15	nef	182	196	
LAFHHVARELHPEYF	15	nef	189	203	
IAPGQMREPRGSDIA	15	pol	223	237	
MREPRGSDIAGTTST	15	pol	228	242	
GSDIAGTTSTLQEQI	15	pol	233	247	
STLQEQIGWMTNNPP	15	pol	241	255	
EOIAWMTSNPPVPVG	15	pol	245	259	
medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.22274468; this v (which was not certification recent review) is the author/funder, who has this made available under a CC-BY	ersion posted May 1 granted medRxiv a l	, 2022. The copyright hold icense to display the prep	der for this preprint print in perpetnity.	267	
PVGEIYKRWIILGLN	15	pol	257	271	
YKRWIILGLNKIVRM	15	pol	262	276	
ILGLNKIVRMYSPVS	15	pol	267	281	
IVRMYSPVSILDIKQ	15	pol	273	287	
SPTSILDIRQGPKEP	15	pol	278	292	
IRQGPKEPFRDYVDR	15	pol	285	299	
GPKEPFRDYVDRFYK	15	pol	288	302	
FRDYVDRFYKTLRAE	15	pol	293	307	
DRFYKTLRAEQASQE	15	pol	298	312	
TLRAEQASQEVKNWM	15	pol	303	317	
RAEQASQEVKNWMTE	15	pol	305	319	
LLVQNANPDCKTILR	15	pol	321	335	
ILKALGPAATLEEMM	15	pol	333	347	
LGPAATLEEMMTACQ	15	pol	337	351	
PSHKARVLAEAMSQA	15		356	370	
		pol			
QRGNFRNQRKTVKCF	15	pol	379	393	
FNCGKEGHTARNCRA	15	pol	393	407	
KEGHQMKDCTERQAN	15	pol	418	432	
MKDCTERQANFLGKI	15	pol	423	437	
QRPLVTIKIGGQLKE	15	pol	495	509	
TPVNIIGRNLLTQIG	15	pol	568	582	
NFPISPIETVPVKLR	15	pol	586	600	
TEMEKEGKISKIGPE	15	pol	626	640	
PSGLKKKKSVTVLDM	15	pol	684	698	
FRKYTAFTIPSINNE	15	pol	711	725	
GSPAIFQSSMTKILE	15	pol	742	756	
SPAIFQSSMTKILEP	15	pol	743	757	
	15	pol	782	796	
IGQHRTKIEELRQHL		-			
IGQHRTKIEELRQHL KDSWTVNDIQKLVGK SWTVNDIQKLVGKLV	15 15	pol pol	836 838	850 852	

VHDIQKLVGKLNWAS	15	pol	841	855	
QKLWGKLNWASQIYP	15	pol	845	859	
WRQLCKLLRGTKALT	15	pol	863	877	
GTKALTEVIPLTEEA	15	pol	872	886	
PLTEEAELELAENRE	15	pol	881	895	
LAENREILKEPVHGV	15	pol	890	904	
TYQIYQEPFKNLKTG	15	pol	925	939	
QEPFKNLKTGKYAKM	15	pol	930	944	
YAKMRSAHTNDVKQL	15	pol	941	955	
GKTPKFKLPIQKETW	15	pol	971	985	
IPEWEFVNTPPLVKL	15	pol	998	1012	
WEFVNTPPLVKLWYQ	15	pol	1001	1015	
medRxiv preprint doi: https://doi.org/10.1101/2022.04.29.22274468; this (which was not certified by pred to very) is the author/funder, who hat It is made available under a CC-B	as granted medRxiv a	license to display the prep ense .	print in perpendity	1030	
KEPIVGAETFYVDGA	15	pol	1018	1032	
EKVYLAWVPAHKGIG	15	pol	1116	1130	
KVYLAWVPAHKGIGG	15	pol	1117	1131	
HSNWRAMASDFNLPP	15	pol	1163	1177	
GKIILVAVHVASGYI	15	pol	1217	1231	
VTSGYIEAEVIPAET	15	pol	1226	1240	
HLKTAVQMAVYIHNF	15	pol	1318	1332	
KTAVQMAVFIHNFKR	15	pol	1320	1334	
AGERIVDIIATDIQT	15	pol	1343	1357	
QKQITKIQNFRVYYR	15	pol	1361	1375	
ISKFRVYYRDSRDPI	15	pol	1367	1381	
SDIKVVPRRKAKIIR	15	pol	1402	1416	
DEELIRTVRLIKLLY	15	rev	9	23	
SNPPPNPEGTRQARR	15	rev	25	39	
SYHCLVCFQTKGLGI	15	tat	31	45	
ITKALGISYGRKKRR	15	tat	39	53	
KALGISYGRKKRRQR	15	tat	41	55	
DHQNLISKQPLPRTQ	15	tat	64	78	
SLQYLALVALVAPKK	15	vif	144	158	
RHFPRIWLHGLGQHI	15	vpr	32	46	
PRIWLHGLGQHIYET	15	vpr	35	49	
ETYGDTWAGVEAIIR	15	vpr	48	62	
DTWAGVEAIIRILQQ	15	vpr	52	66	
EAIIRILQQLLFIHF	15	vpr	58	72	
QLLFIHFRIGCRHSR	15	vpr	66	80	
IHFRIGCRHSRIGVT	15	vpr	70	84	
VLAIVALVVATIIAI	15	vpu	5	19	

Figure 1



Figure 1

Figure 2





Figure 2



Supplemental Figure 1

Supplemental Figure 2



Supplemental Figure 2

Supplemental Figure 3



Supplemental Figure 3